Dr Miriam Butler, PhD
Position:
- Postdoctoral Fellow, Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia
Credentials:
- PhD at University of Adelaide
- BHlthSc(Honours) at University of Adelaide
- BMedSc at Flinders University
Websites:
Biography:
Dr. Miriam Butler completed her PhD at the University of Adelaide, Australia under the supervision of Dr. Wayne Tilley and Dr. Theresa Hickey. Dr. Butler’s main research area of interest is the molecular mechanisms of cancer, particularly factors that modulate disease progression and/or metastasis and that may ultimately be useful biomarkers or therapeutic targets. Since 2013 Dr. Butler has been a postdoctoral fellow at the Vancouver Prostate Centre where, under the supervision of Dr. Paul Rennie and Dr. Artem Cherkasov, she is working on the development of novel small molecule inhibitors targeting members of the ETS family of transcription factors. She hopes become an independent researcher and work toward her long term career goal to make a significant impact in prostate cancer research by performing innovative research that has potential clinical applications
Best publications:
Butler MS*, Roshan-Moniri M*, Hsing M*, Rennie PS, Cherkasov A, 2014 Orphan Nuclear Receptors as drug targets for the treatment of prostate and breast cancers. Cancer Treatment Reviews 40(10):1037-52. *Co-First Author
Philp LK, Butler MS, Hickey TE, Butler LM, Tilley WD, Day TK. 2013 SGTA: A new player in the molecular co-chaperone game. Hormones and Cancer 4(6):343-57.
Butler MS, Ricciardelli C, Tilley WD, & Hickey TE, 2013 Androgen receptor protein levels are significantly lower in serous ovarian cancer compared to benign or borderline disease but are not altered by cancer stage or metastatic progression. Hormones and Cancer 4(3):154-64.
Callen DF, Ricciardelli C, Butler M, Stapleton A, Stahl J, Kench JG, Horsfall DJ, Tilley WD, Schulz R, Nesland JM, Neilsen PM, Kumar R, Holm R. 2010 Co-expression of the androgen receptor and the transcription factor ZNF652 is related to prostate cancer outcome. Oncology Reports, 23(4):1045-52.
Prostate Cancer, Experimental Therapeutics, Androgen Receptor Signalling.
